Investigational drug · Phase 3
SEP-363856
Also called: Ulotaront
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
5 still active
All registered trials
31
Any phase or sponsor naming "SEP-363856"
First trial start
2022
Nov 9, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SEP-363856", any sponsor or status.
Conditions studied
As listed on its trial records.
- Generalized Anxiety Disorder
- Schizophrenia
- Major Depressive Disorder
Approved drugs for the same conditions: Depression (major depressive disorder) · Schizophrenia · Anxiety disorders · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "SEP-363856" as an intervention, largest first.
- A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety DisorderPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07786454 · 1,120 participants (planned) · Start Oct 8, 2026 · Primary completion May 26, 2029
Drug: SEP-363856 · For: Generalized Anxiety Disorder
Sites: Jacksonville, Florida; Orlando, Florida; Jamaica, New York · 4 sites in all
- A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05593029 · 929 participants · Start Nov 9, 2022 · Primary completion Nov 6, 2025
Drug: SEP-363856 · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 77 sites in all
- A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety DisorderPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07759128 · 576 participants (planned) · Start Jul 28, 2026 · Primary completion Dec 6, 2028
Drug: SEP-363856 · For: Generalized Anxiety Disorder
Sites: Saraland, Alabama; Tucson, Arizona; Encino, California · 27 sites in all
- A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaPivotal-lookingActive, not recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06894212 · 538 participants · Start Feb 28, 2025 · Primary completion Oct 20, 2026
Drug: SEP-363856 · For: Schizophrenia
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Rogers, Arkansas · 73 sites in all
- A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT04092686 · 464 participants · Start Oct 14, 2019 · Primary completion Jun 14, 2023
Drug: SEP-363856 75mg; SEP-363856 100mg and 1 more · For: Schizophrenia
Sites: Rogers, Arkansas; Anaheim, California; Bellflower, California · 53 sites in all
- A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT04072354 · 463 participants · Start Sep 17, 2019 · Primary completion May 12, 2023
Drug: SEP-363856 50mg; SEP-363856 75mg and 1 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Anaheim, California; Bellflower, California · 53 sites in all
- A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With SchizophreniaPivotal-lookingTerminated
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT04109950 · 463 participants · Start Nov 20, 2019 · Primary completion Nov 9, 2023
Drug: SEP-363856 · For: Schizophrenia
Sites: Little Rock, Arkansas; Rogers, Arkansas; Anaheim, California · 78 sites in all
- A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05729373 · 434 participants · Start Mar 8, 2023 · Primary completion Sep 26, 2025
Drug: SEP-363856; Placebo · For: Generalized Anxiety Disorder
Sites: Huntsville, Alabama; Phoenix, Arizona; Culver City, California · 83 sites in all
- A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety DisorderPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07767903 · 384 participants (planned) · Start Aug 6, 2026 · Primary completion Oct 25, 2028
Drug: SEP-363856; Placebo · For: Generalized Anxiety Disorder
Sites: Phoenix, Arizona; Los Angeles, California; Redlands, California · 21 sites in all
- A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT04115319 · 305 participants · Start Nov 21, 2019 · Primary completion Dec 30, 2022
Drug: SEP363856; quetiapine XR · For: Schizophrenia
Sites: Cerritos, California; Oakland, California; Oceanside, California · 42 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- Antipsychotic-like effects of TAAR1 agonists and D2 receptor blockers are mediated through distinct modulation of striatal neuronal dynamics.
Huang S, Yang SM, Bellier L, et al. · Mol Psychiatry 2026
- Medicinal chemistry advances of TAAR1 agonists: SAR, structural innovation, and mechanistic insights.
Zhang W, Wu W, Gao J, et al. · Eur J Med Chem 2026
- Design and synthesis of long-acting prodrugs of SEP-363856 with sustained antipsychotic-like activity.
Gao W, Xue Y, Zhang J, et al. · Bioorg Chem 2026
- Structure based discovery of antipsychotic-like TAAR1 agonists.
Huang S, Liu H, Wu Y, et al. · Nat Commun 2026
- Ulotaront (SEP363856) Reduces Dopamine Release and Synthesis Capacity in Mice and Patients With Schizophrenia.
Svenningsson P · Biol Psychiatry 2026
Also in development for Generalized Anxiety Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- BuagafuranPhase 32 trials
Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder
- Buagafuran mimicPhase 32 trials
Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder
- Toludesvenlafaxine Hydrochloride Sustained-releasePhase 31 trial
Luye Pharma Group Ltd. · Generalized Anxiety Disorder
- ENX-102ENX-102 -dose, ENX-102 mid-dosePhase 23 trials
Engrail Therapeutics INC · General Anxiety Disorder, Social Anxiety Disorder (SAD), Generalized Anxiety Disorder
- RE104Phase 23 trials
Reunion Neuroscience Inc · Adjustment Disorder, Generalized Anxiety Disorder, Postpartum Depression
- CYB004Phase 21 trial
Cybin IRL Limited · Generalized Anxiety Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Otsuka.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.